1 |
Das R, Hyer RN, Burton P, Miller JM, Kuter BJ. Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Hum Vaccin Immunother 2023;19:2153532. [PMID: 36629006 DOI: 10.1080/21645515.2022.2153532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Salvagno GL, Pighi L, Henry BM, Valentini M, Tonin B, Bragantini D, Gianfilippi G, De Nitto S, Plebani M, Lippi G. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity. Clin Chem Lab Med 2023. [PMID: 36722026 DOI: 10.1515/cclm-2023-0055] [Reference Citation Analysis]
|
3 |
Alfouzan W, Altawalah H, AlSarraf A, Alali W, Al-Fadalah T, Al-Ghimlas F, Alajmi S, Alajmi M, AlRoomi E, Jeragh A, Dhar R. Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait. Vaccines (Basel) 2023;11. [PMID: 36851214 DOI: 10.3390/vaccines11020336] [Reference Citation Analysis]
|
4 |
Kodali L, Budhiraja P, Gea-Banacloche J. COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Front Med (Lausanne) 2022;9:1060265. [PMID: 36507509 DOI: 10.3389/fmed.2022.1060265] [Reference Citation Analysis]
|
5 |
Murphy RL, Paramithiotis E, Sugden S, Chermak T, Lambert B, Montamat-sicotte D, Mattison J, Steinhubl S. The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials. Front Immunol 2022;13:923106. [DOI: 10.3389/fimmu.2022.923106] [Reference Citation Analysis]
|
6 |
Chen L, Qi X, Liang D, Li G, Peng X, Li X, Ke B, Zheng H, Liu Z, Ke C, Liao G, Liu L, Feng Q. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants. Vaccines 2022;10:1502. [DOI: 10.3390/vaccines10091502] [Reference Citation Analysis]
|